The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy

Biliary tract cancers (BTCs) represent a heterogeneous group that includes intrahepatic cholangiocarcinomas (CCAs), perihilar-CCAs or Klatskin tumors, extrahepatic-CCAs, and gallbladder adenocarcinoma. These entities have distinct demographics, risk factors, clinical presentation, and molecular char...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacology & therapeutics (Oxford) 2020-06, Vol.210, p.107517, Article 107517
Hauptverfasser:	Palmieri, L.-J., Lavolé, J., Dermine, S., Brezault, C., Dhooge, M., Barré, A., Chaussade, S., Coriat, R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biliary tract cancers Biliary Tract Neoplasms - genetics Biliary Tract Neoplasms - immunology Biliary Tract Neoplasms - mortality Biliary Tract Neoplasms - therapy Biomarkers, Tumor - genetics Cholangiocarcinoma Clinical Decision-Making Genome sequencing Humans Immunotherapy Immunotherapy - adverse effects Immunotherapy - mortality Life Sciences Molecular Targeted Therapy - adverse effects Molecular Targeted Therapy - mortality Precision Medicine Targeted therapy Treatment Outcome Tumor Microenvironment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!